Cambridge Investment Research Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.25M	Buy	21,829 +16,612	+318%	+$910K	﹤0.01%	1941
2026 Q1	$295K	Sell	5,217 -48	-0.9%	-$2.8K	﹤0.01%	3307
2025 Q4	$313K	Buy	+5,265	New	+$287K	﹤0.01%	3157
2024 Q4	–	Sell	-3,510	Closed	-$247K	–	3478
2024 Q3	$247K	Buy	3,510 +440	+14%	+$36.8K	﹤0.01%	2980
2024 Q2	$253K	Buy	3,070 +524	+21%	+$43.6K	﹤0.01%	2838
2024 Q1	$222K	Sell	2,546 -305	-11%	-$27.3K	﹤0.01%	2942
2023 Q4	$275K	Buy	2,851 +42	+1%	+$3.72K	﹤0.01%	2656
2023 Q3	$249K	Sell	2,809 -1,253	-31%	-$111K	﹤0.01%	2645
2023 Q2	$352K	Sell	4,062 -1,027	-20%	-$96.6K	﹤0.01%	2414
2023 Q1	$495K	Sell	5,089 -1,049	-17%	-$109K	﹤0.01%	2080
2022 Q4	$635K	Buy	6,138 +460	+8%	+$43.2K	﹤0.01%	1840
2022 Q3	$481K	Sell	5,678 -2,302	-29%	-$205K	﹤0.01%	1963
2022 Q2	$661K	Sell	7,980 -454	-5%	-$36.1K	﹤0.01%	1746
2022 Q1	$650K	Sell	8,434 -3,191	-27%	-$267K	﹤0.01%	1902
2021 Q4	$1.03M	Sell	11,625 -9,855	-46%	-$813K	﹤0.01%	1562
2021 Q3	$1.66M	Buy	21,480 +3,314	+18%	+$261K	0.01%	1208
2021 Q2	$1.52M	Buy	18,166 +8,568	+89%	+$679K	0.01%	1262
2021 Q1	$725K	Buy	9,598 +4,154	+76%	+$339K	﹤0.01%	1645
2020 Q4	$477K	Buy	5,444 +1,287	+31%	+$102K	﹤0.01%	1798
2020 Q3	$316K	Sell	4,157 -74	-2%	-$7.49K	﹤0.01%	1899
2020 Q2	$522K	Buy	+4,231	New	+$421K	﹤0.01%	1524
2018 Q1	–	Sell	-2,509	Closed	-$224K	–	2157
2017 Q4	$224K	Sell	2,509 -28	-1%	-$2.44K	﹤0.01%	1845
2017 Q3	$236K	Buy	2,537 +192	+8%	+$17K	﹤0.01%	1711
2017 Q2	$213K	Buy	+2,345	New	+$213K	﹤0.01%	1714

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Cambridge Investment Research Advisors's BMRN Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 318% in Q2 2026, buying an estimated $910K and bringing the position to 21,829 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1941.

Cambridge Investment Research Advisors first reported a position in BMRN in Q2 2017 and has held it in 24 quarters since. The position peaked at $1.66M in Q3 2021. 142 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Cambridge Investment Research Advisors held 21,829 shares of BioMarin Pharmaceuticals worth $1.25M as of Q2 2026.
Cambridge Investment Research Advisors bought 16,612 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $910K.
BioMarin Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1941 holding.
Cambridge Investment Research Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2017 and has held it in 24 quarters since.
Cambridge Investment Research Advisors's BioMarin Pharmaceuticals position peaked at $1.66M in Q3 2021.
142 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.